Blood test could flag rapid kidney failure risk in diabetes

NCT ID NCT04791358

Ongoing Diagnosis Sponsor: Renalytix AI, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial is testing whether a diagnostic test called KidneyIntelX can help doctors better manage patients with type 2 diabetes and early-stage chronic kidney disease. The test predicts the risk of rapid kidney function decline over five years. Researchers will see if using this test leads to more patients receiving recommended treatments like blood pressure control and certain medications. The goal is to see if the test improves clinical decisions and ultimately slows kidney damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KidneyIntelX, a diagnostic test that predicts the risk of rapid kidney function decline in people with type 2 diabetes and chronic kidney disease.
What this could lead to: If effective, this test could help doctors identify high-risk patients earlier and tailor treatments to slow kidney damage.
What could go wrong: The test's accuracy and real-world impact are still being evaluated; it may not change outcomes for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC KIDNEY DISEASE

Contacts and locations

Locations

Delmar Family Medicine

Slingerlands, New York, 12159, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.